FDA Advisory Panel Recommends Loosening Compounding Restrictions for Six Experimental Peptides
An FDA advisory panel recently voted to recommend allowing compounding pharmacies to produce six out of seven experimental peptides, despite warnings from agency scientists regarding their safety and efficacy. The panel, which included several sellers of the experimental peptides, favored the move to accommodate high commercial demand and the influence of Health Secretary Robert F. Kennedy Jr., a proponent of the substances. While the panel's recommendation does not grant full FDA approval, it would allow specialty pharmacies to create custom medications from these peptides, such as BPC-157 and TB-500. However, medical experts and agency scientists expressed concern over the lack of robust human clinical trials for these compounds. Researchers noted that while peptides are popular in the wellness space, many currently lack long-term data on human safety. The administration announced that the final decision rests with the FDA, which may follow the panel's recommendation or be overruled by the administration. If approved, the peptides will be available via prescription from compounding pharmacies rather than standard pharmaceutical factories.